613 related articles for article (PubMed ID: 22583603)
1. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
2. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
3. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers.
Hristozova T; Konschak R; Budach V; Tinhofer I
Cytometry A; 2012 Jun; 81(6):489-95. PubMed ID: 22438318
[TBL] [Abstract][Full Text] [Related]
4. The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN).
Hristozova T; Konschak R; Stromberger C; Fusi A; Liu Z; Weichert W; Stenzinger A; Budach V; Keilholz U; Tinhofer I
Ann Oncol; 2011 Aug; 22(8):1878-85. PubMed ID: 21525401
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
7. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
[TBL] [Abstract][Full Text] [Related]
8. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.
Holz C; Niehr F; Boyko M; Hristozova T; Distel L; Budach V; Tinhofer I
Radiother Oncol; 2011 Oct; 101(1):158-64. PubMed ID: 21665310
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
13. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
15. Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Jensen AD; Krauss J; Weichert W; Bergmann ZP; Freier K; Debus J; Münter MW
Radiat Oncol; 2011 Sep; 6():122. PubMed ID: 21942981
[TBL] [Abstract][Full Text] [Related]
16. [Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Zhang X; Wang J; Wu W; Ma L; Liu M; Zhao F; Huang D
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 49(7):558-63. PubMed ID: 25257270
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Harrington K; Temam S; Mehanna H; D'Cruz A; Jain M; D'Onofrio I; Manikhas G; Horvath Z; Sun Y; Dietzsch S; Dubinsky P; Holeckova P; El-Hariry I; Franklin N; Biswas-Baldwin N; Legenne P; Wissel P; Netherway T; Farrell J; Ellis C; Wang-Silvanto J; Amonkar M; Ahmed N; Santillana S; Bourhis J
J Clin Oncol; 2015 Dec; 33(35):4202-9. PubMed ID: 26527790
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
